The BRAF V600E mutation is the most common genetic alteration in thyroid cancer. However, its clinicopathological significance and clonal mutation frequency remain unclear. To clarify the inconsistent results, we investigated the association between the allelic frequency of BRAF V600E and the clinicopathological features of classic papillary thyroid carcinoma (PTC). Tumour tissues from two independent sets of patients with classic PTC were manually microdissected and analysed for the presence or absence of the BRAF mutation and the mutant allelic frequency using quantitative pyrosequencing. For external validation, the Cancer Genome Atlas (TCGA) data were analysed. The BRAF V600E mutation was found in 264 (82.2%) out of 321 classic PTCs in the training set. The presence of BRAF V600E was only associated with extrathyroidal extension and the absence of thyroiditis. In BRAF V600E-positive tumours, the mutant allelic frequency varied from 8 to 41% of the total BRAF alleles (median, 20%) and directly correlated with tumour size and the number of metastatic lymph nodes. Lymph node metastases were more frequent in PTCs with a high (R20%) abundance of mutant alleles than in those with a low abundance of mutant alleles (PZ0.010). These results were reinforced by validation dataset (nZ348) analysis but were not reproduced in the TCGA dataset. In a population with prevalent BRAF mutations, quantitative analysis of the BRAF mutation could provide additional information regarding tumour behaviour, which is not reflected by qualitative analysis. Nonetheless, prospective studies are needed before the mutated allele percentage can be considered as a prognostic factor.
Introduction
The V600E BRAF mutation is the most common genetic alteration in papillary thyroid carcinoma (PTC). The prevalence of the BRAF V600E mutation varies according to the histological subtype; the mutation is frequent in the tall cell variant and classic PTC, but absent in the cribriform-morular variant (Trovisco et al. 2005) . The clinical importance of the BRAF mutation derives from its role as a prognostic factor. Recently, mortality has been related to BRAF mutation status, which had previously been considered supplemental information to conventional prognostic factors (Xing et al. 2013) . Considering the availability of current targeted therapies that include a BRAF inhibitor, the identification of the BRAF mutation may also be a good candidate marker for the prediction of response to targeted therapies. Nevertheless, there remains controversy surrounding the prognostic role of the BRAF mutation, as multiple studies have failed to illustrate a prognostic role for the BRAF mutation (Kim et al. 2005 , Cheng et al. 2011 , Eloy et al. 2011 , Nam et al. 2012 , Paulson et al. 2012 , Sassolas et al. 2012 .
In the studies mentioned above, the BRAF mutation was evaluated in a qualitative manner. The presence of the BRAF mutation in tissues was considered important in the analysis. However, the subclonality of the BRAF mutation in PTCs has recently been suggested (Guerra et al. 2012a) . In this context, the quantification of the mutated allele was emphasised in terms of predicting prognosis (Guerra et al. 2012b) ; however, several studies have shown results contradictory to those findings, as determined by the quantification of mutated alleles (Gandolfi et al. 2013 ) and immunohistochemical (IHC) staining (Ghossein et al. 2013) . The proper value of the quantification of the mutated allele remains in debate and requires further evaluation.
In addition, there is a large variation in the prevalence of the BRAF mutation in PTCs between countries. Generally, the Asian population (especially in Koreans) exhibits up to an 86% incidence rate for the BRAF mutation compared with a rate that is typically below 60% in other populations (Chung et al. 2006 , Lee et al. 2007 , Jung et al. 2010 , Xing et al. 2013 . In this group, no quantification of mutated allele was evaluated.
Thus, in this study, the implication of quantifying the BRAF mutation will be evaluated in a population in which the mutation is highly prevalent.
Materials and methods

Patients and specimens
We retrospectively enrolled two independent sets comprising 670 PTC patients who underwent surgery at Seoul St Mary's Hospital between 2012 and 2014. Classic PTCs were only selected to minimise the bias due to the inclusion of different tumour types. Classic PTCs with tall cell features were excluded. The training set comprised 322 consecutive patients with classic PTC who underwent surgery between February 2012 and January 2013. The independent validation dataset was obtained from a separate cohort of 348 consecutive classic PTC patients (who underwent surgery between February 2013 and December 2013) with the same enrolment criteria. We excluded classic PTCs with marked intratumoural lymphocytic infiltration or densely sclerotic stroma. One representative formalin-fixed and paraffin-embedded tissue block of classic PTCs was selected from each case by a pathologist after reviewing the haematoxylin and eosin-stained slides. In cases with multifocal PTC foci, the largest tumours were chosen for the study. All specimens were collected in accordance with the institutional protocols of our hospital.
Genomic DNA extraction from tumour tissue
Briefly, paraffin sections of 5-mm thickness were heated for 60 min at 57 8C, deparaffinised in xylene, rehydrated in decreasing concentrations of alcohols and air dried. Tumour areas were manually microdissected under a stereomicroscope to exclude possible contamination by the surrounding normal tissue. Genomic DNA was extracted from the microdissected tumour tissue using the QIAamp DNA FFPE Tissue kit (Qiagen).
PCR
A 98-bp fragment of exon 15 of the BRAF gene was amplified through PCR using the PyroMark PCR kit (Qiagen). The PCR mixtures included 12.5 ml of PyroMark PCR Master Mix (Qiagen), 2.5 ml of CoralLoad Concentrate (Qiagen), 5 ml of Q-solution, 0.5 ml of 10 mM forward primer (5 0 -biotin-TTCTTCATGAAGACCTCA-CAGTAA-3 0 ), 0.5 ml of 10 mM reverse primer (5 0 -CCAGA-CAACTGTTCAAACTGATG-3 0 ), and 4 ml of 30 ng/ul genomic DNA in a final reaction volume of 25 ml. The PCR conditions were as follows: an initial activation at 95 8C for 15 min; 42 cycles of 30 s at 95 8C, 30 s at 53 8C and 30 s at 72 8C and a final extension at 72 8C for 10 min. The amplicons were evaluated through 2% agarose gel electrophoresis.
Pyrosequencing
After PCR, biotinylated PCR products were immobilised on Streptavidin Sepharose High Performance beads (GE Healthcare, Piscataway, NJ, USA). The reaction mixture for DNA immobilisation consisted of 2 ml of Streptavidin Sepharose High Performance beads, 40 ml of PyroMark Binding Buffer (Qiagen), 28 ml of water (Qiagen), and 10 ml of PCR product in a final reaction volume of 80 ml. Single-stranded DNA for pyrosequencing was prepared on the PyroMark Q24 Vacuum Workstation (Qiagen) according to the manufacturer's instructions. Subsequently, the single-stranded DNA was annealed to the sequencing primer (5 0 -CCACTCCATCGAGATT-3 0 )
in a reaction mixture containing 0.8 ml of sequencing primer and 24.2 ml of PyroMark annealing buffer through a 2-min incubation at 80 8C. The sequencing primer was designed to include an analysis of codons 599-601 of BRAF. Pyrosequencing was performed using PyroMark Gold Q24 reagents (Qiagen) on a PyroMark Q24 system (Qiagen), and the data were analysed using the PyroMark Q24 software, version 2.0.6 (Qiagen 
Results
Baseline characteristics of the study population
The patient demographics and clinicopathological features are summarised in in the baseline characteristics between the training and validation sets.
Approach to the status of BRAF mutation by conventional methods (whether positive or negative)
There was no association between BRAF mutational status and either age at diagnosis, tumour size or multifocality in the training and validation sets. The presence of extrathyroidal extension, a higher incidence of pT3-4 and the absence of chronic lymphocytic thyroiditis were significantly associated with BRAF in two independent sets (Table 1) .
Distribution of mutated BRAF allele percentage
In only the BRAF-positive tumours, the median for the frequency of allele mutation was 20% (range 8-41%) and 20% (range 8-42%), respectively, in the training and validation sets. PTCs with thyroiditis had a lower percentage of the mutated allele than those without thyroiditis. We compared our results with previously published data and the results obtained from the TCGA dataset. A detailed distribution of the allele mutation percentages is summarised in Table 2 . Studies using next-generation sequencing (NGS) technology for BRAF mutation identification showed higher mutant allele percentages than those using pyrosequencing.
Impact of BRAF V600E allele percentage on clinicopathological features
When the study population was categorised into BRAF mutation negative (mutated allele frequency !8%) and low allele-mutation (allele frequency 8-19%) and high allele-mutation (allele frequency R20%) groups (based on the cut-off value derived from the median value of studied subjects), there was no significant difference in the clinicopathological features between the negative and low allele-mutation groups in two independent sets (Tables 3 and 4) . However, the high allele-mutation group had a larger tumour size and a higher incidence of extrathyroidal extension, pT3-4 and lymph node metastasis than the negative and low allele-mutation groups (Table 3) . These results were also consistent with those from the validation and total sets (Tables 4 and 5) . Correlation between mutated allele frequency and tumour progression
Among the tumours with the BRAF V600E mutation, the frequency of mutated alleles directly correlated with the tumour size (P!0.001, Fig. 1a and P!0.001, Fig. 1b respectively) and the number of metastatic lymph nodes (P!0.001, Fig. 2a and P!0.001, Fig. 2b the training set (Supplementary Table 1 , see section on supplementary data given at the end of this article). Among the PTMCs with BRAF mutation, the high allelemutation group was significantly associated with a larger tumour size as well as the presence of extrathyroidal extension and the absence of thyroiditis (Supplementary  Table 2 ). However, there was no significant relationship between the mutated allele percentages and lymph node metastasis (Supplementary Table 2 ).
Multivariate analysis of lymph node metastasis prediction
In the univariate analysis, lymph node metastasis was significantly associated with the size of the tumour, patient age, a high percentage of a mutated allele, tumour multifocality, extrathyroidal extension and lymphatic invasion. However, in the multivariate analysis, the significance of multifocality and the percentage of mutated alleles were lost in the training and validation sets (Table 6 ).
TCGA validation set
Of the 400 PTC patients available for DNA sequencing data in TCGA, we selected only 108 patients with classic PTC to analyse the relationship between pathological features and BRAF mutation status (Table 7) . BRAF positivity was correlated with the presence of extrathyroidal extension (PZ0.001) and pT3-4 stage (PZ0.007) but not with other factors. We further categorised 81 patients with BRAF V600E into low allele-mutation (allele frequency 4-35%) and high allele-mutation (allele frequency R36%) groups (based on the cut-off value derived from the median value of studied subjects). In the semi-quantitative analysis, the increase in mutated allele frequency was significantly associated with extrathyroidal extension and high pT stage. However, there was no correlation between the frequency of mutated alleles and tumour size or lymph node metastases.
Discussion
In this study, we evaluated the clinical implication of a quantitative approach of describing BRAF mutations (the percentage of mutated alleles) in a population with a high BRAF mutation prevalence. We found that the quantitative analysis of BRAF mutation provided additional information regarding tumour behaviour that was not reflected by a qualitative analysis in both the training and validation sets. In addition, a substantial portion of PTC cases showed intratumoural heterogeneity in terms of the BRAF mutation. In our training set, 82.3% of the population conventionally showed the BRAF mutation, which is consistent with previous Korean studies (Chung et al. 2006 , Kim et al. 2009 , Jung et al. 2010 . The BRAF positivity rate appears to be higher in our study than in other studies performing a quantitative analysis of BRAF mutations (Guerra et al. 2012a ,b, Gandolfi et al. 2013 . As the incidence of BRAF mutation in PTCs varies Using a conventional approach, there was no significant association of BRAF positivity with clinical/ pathological parameters other than the presence of extrathyroidal extension and the absence of thyroiditis. The association of BRAF mutation with the presence of extrathyroidal extension and the absence of thyroiditis , Nam et al. 2012 ) and the absence of thyroiditis (Sargent et al. 2006 , Kim et al. 2009 ) was concordant with previous studies. By contrast, taking a quantitative approach to describe the BRAF-positive population revealed that groups with a high percentage of allelic mutation were closely related to poor prognostic parameters (such as tumour size, extrathyroidal extension, lymph node metastasis and the number of metastatic lymph nodes) compared with low mutation-percentage groups. A low percentage of allelic mutation was related to a high incidence of thyroiditis. PTCs with a low BRAF mutation-percentage had a clinical behaviour similar to that of BRAF-negative tumours. It is possible that there was a high prevalence of patients with a low percentage of mutant alleles in previous studies that described a lack of a relationship between BRAF positivity and unfavourable parameters. Analysis of the percentage of mutated alleles in a population with prevalent BRAF mutations may provide clues to explain the discordant role of BRAF mutations in determining patient prognosis. Intratumoural heterogeneity has been recognised since Nowell (1976) suggested that tumour heterogeneity could be acquired during progression. Several methods have been applied to detect intratumoural heterogeneity such as IHC staining, fluorescence in situ hybridisation, microarray analysis or DNA sequencing. In various cancers, intratumoural heterogeneity has already been demonstrated and has been related to patient prognosis or treatment response (Taniguchi et al. 2008 , Gerlinger et al. 2012 , Seol et al. 2012 , Anaka et al. 2013 ). In our study, the BRAF mutation status was also found to be heterogeneous via quantitative pyrosequencing. Recently, the efficacy of several tyrosine kinase inhibitors, especially those targeting BRAF kinase activity, has been investigated in refractory thyroid carcinomas. The quantification of the intratumoural heterogeneity of BRAF mutations would be useful to predict the response to such therapies.
The correlation between the percentage of allele mutation and the tumour size appears significant in terms of evaluating the role of the BRAF mutation in carcinogenesis. As suggested by the heterogeneity of RET/PTC rearrangements in post-Chernobyl PTCs (Unger et al. 2004) , the heterogeneity of the BRAF mutation in PTCs could be caused by BRAF mutation development in tumour initiation with a later emergence of clones without mutation or by selection for cells harbouring the BRAF mutation during tumour progression. Considering the relationship between the percentage of mutated alleles and tumour size, the latter hypothesis based on the clonal evolution theory (Nowell 1976) appears plausible. This hypothesis is supported by several studies that analysed the status of the BRAF mutation in both primary lesions and metastases (Oler et al. 2005 , Vasko et al. 2005 . However, the issue of BRAF mutational heterogeneity and clonal evolution in thyroid cancer is In our study, the quantification of the mutated allele was evaluated using pyrosequencing. We observed that w30% of PTCs with BRAF V600E had more than 25% of the mutated allele. These results are comparable to those obtained in the pyrosequencing study by Guerra et al. (2012a,b) . However, these pyrosequencing data are in contrast to the results achieved using NGS and IHC staining. Nikiforova et al. (2013) evaluated BRAF mutated alleles using NGS and reported that 80% of PTCs with BRAF V600E had more than 25% of the mutated alleles. In the TCGA dataset, 86% of classic PTCs with BRAF V600E had more than 25% of the mutated alleles. In studies using a mutation-specific antibody against the BRAF V600E protein, the immunostaining pattern was homogenous in most PTCs, supporting the BRAF mutation as a clonal event (Bullock et al. 2012 , Koperek et al. 2012 , Ghossein et al. 2013 . Recently, de Biase et al. (2014) have found the heterogeneous distribution of BRAF V600E within the PTC using both immunohistochemistry and quantitative DNA analytical methods. They also revealed the correspondence between mutated allele percentage and the extent and distribution of the BRAF V600E immunoreactivity in a subset of PTCs. However, there is still a puzzling discrepancy between the proportion of BRAF V600E-immunoreactive cells and mutant allele percentage based on DNA analysis in the study by de Biase et al. We are not sure as to why pyrosequencing underestimated the fraction of alleles carrying BRAF V600E compared with NGS. The clonal evolution theory is also contradictory to the previous belief that the BRAF mutation is an initial event in thyroid carcinoma carcinogenesis, which was supported by experimental methods (Knauf et al. 2005) .
Considering that 69.6% (in training set) and 79.0% (in validation set) of the studied population were PTMC, it may be interesting to evaluate the possibility of the BRAF mutated allele percentage in PTMC as a biomarker for tumour aggressiveness. A high BRAF mutated allele percentage was related to tumour size, extrathyroidal extension and the absence of thyroiditis but not with lymph node metastasis. Therefore, the utility of BRAF mutation quantitative analysis in PTMC as a progression marker is not yet justified.
As there were many PTMCs in the current study, there may be some concern that contamination by normal tissue surrounding the tumour cells could be responsible for the results. In the presence of thyroiditis in particular, contamination of tumour cells by lymphoid cells should be considered, as mentioned in a previous study (Marotta et al. 2013) . To prevent the underestimation of mutated allele percentages by the contamination of non-tumour cells, careful microdissection was performed and tumours with marked lymphocytic infiltration were excluded in our study. The exclusion of PTMC or PTC with thyroiditis did not alter the association between the mutated allele percentages and tumour size. Although the association of the mutated allele percentage with the number of lymph nodes lost significance after the exclusion of PTMC, a significant association was still maintained after the exclusion of PTC with thyroiditis. Recently, a normalisation method has been introduced by de Biase et al. (2014) to overcome the problem of normal cell contamination. They normalised the frequency of mutated alleles to the real amount of tumour cells within each PTC sample. Most samples showed an increase in the percentage of mutated allele after normalisation. Thus, the inevitable contamination of non-tumoural cells still remained as fundamental weakness of the current study.
As this study did not have a follow-up period sufficient to estimate patient prognosis, the prognostic implications of a high percentage of BRAF mutation are limited. In addition, the same methodology should be evaluated in fine-needle aspiration samples, which could help with PTC patient management before surgery. If similar results are obtained, surgical decisions could be made based on the quantitative approach in cytology samples. However, as quantitative analysis of cytology samples may differ from that of tissue microdissection, this requires further evaluation in a future study. We used an arbitrary cut-off of 20% based on the median value for risk stratification. It may be arguable whether our results can be generalised. Although the mutated allele percentage was found to be a predictor of lymph node metastases in the univariate analysis, this relationship lost significance in the multivariate analysis. In the TCGA validation dataset, we did not find any relationship between the mutated allele percentage and lymph node metastasis or tumour size. Thus, prospective studies are needed before the mutated allele percentage can be considered to be a prognostic factor for predicting lymph node metastasis.
In conclusion, an allelic mutation rate high above the median value is associated with PTC aggressiveness in terms of tumour size and the number of lymph node metastases. Therefore, quantitative analysis of the BRAF mutation in mutation-prevalent populations may provide accurate characteristics of tumour behaviour among BRAF-positive PTCs.
